Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid

  • Authors:
    • Daniel Glenn Kindell
    • Rick Wayne Keck
    • Jerzy Jankun
  • View Affiliations

  • Published online on: April 1, 2015     https://doi.org/10.3892/etm.2015.2399
  • Pages: 2339-2343
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Plasminogen activator inhibitor (PAI)-1 is a serpin glycoprotein that can stabilize blood clots by inhibiting fibrinolysis. However, wild‑type PAI‑1 has the disadvantage of a short half‑life of ~2 h. A very long half‑life (VLHL) PAI‑1 mutant was developed previously with an active‑form half‑life of >700 h, making it a possible candidate for use in hemorrhagic therapy. Current treatments for mitigating hemorrhage, other than inducers of blood clotting, are limited to lysine analog antifibrinolytics, including 6‑aminocaproic acid and tranexamic acid. VLHL PAI‑1 has been previously demonstrated to limit bleeding; however, the efficacy of this protein compared with lysine analog antifibrinolytics has not been investigated. The aim of the current study was to compare the clot stabilizing properties of the novel antifibrinolytic VLHL PAI‑1 with those of 6‑aminocaproic acid in reference plasma. Using thromboelastographic analysis, VLHL PAI‑1 exhibited an IC50 (half maximal inhibitory concentration) of 8.8x10‑8 mol/l, while 6‑aminocaproic acid showed an IC50 of 1.6x10‑4 mol/l. However, at doses of >9.0x10‑7 mol/l, VLHL PAI‑1 exhibited a delay in the onset of clot formation, which may be attributed to thrombin inhibition by excess PAI‑1. The inhibition of tissue plasminogen activator by VLHL PAI‑1 demonstrated improved efficacy over 6‑aminocaproic acid in mitigating hemorrhage. In addition, patients with a PAI‑1 deficiency, which causes blood clots to lyse rapidly resulting in profuse bleeding, may benefit from the application of VLHL PAI-1 as an antihemorrhagic therapy.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 9 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kindell DG, Keck RW and Jankun J: Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Exp Ther Med 9: 2339-2343, 2015
APA
Kindell, D.G., Keck, R.W., & Jankun, J. (2015). Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Experimental and Therapeutic Medicine, 9, 2339-2343. https://doi.org/10.3892/etm.2015.2399
MLA
Kindell, D. G., Keck, R. W., Jankun, J."Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid". Experimental and Therapeutic Medicine 9.6 (2015): 2339-2343.
Chicago
Kindell, D. G., Keck, R. W., Jankun, J."Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid". Experimental and Therapeutic Medicine 9, no. 6 (2015): 2339-2343. https://doi.org/10.3892/etm.2015.2399